WELCOME TO
RNAiScience Data Hall
This website was created for healthcare professionals to provide access to educational and scientific information about Alnylam's RNAi platform and our data from congresses and publications.
Therapeutic Areas
Science of RNAi
Video
RNAi Mechanism of Action
This video highlights the mechanism of action (MOA) of RNAi therapeutics and its role in silencing gene expression. This video is intended to be viewed in its entirety.
Congresses
Publications
Transthyretin Amyloidosis (ATTR)
Continuous Vutrisiran Reduces Cardiovascular Events and Hospitalizations in Patients With Transthyretin Amyloidosis With Cardiomyopathy in the HELIOS-B One-Year Open Label Extension
Journal of Cardiac Failure
Transthyretin Amyloidosis (ATTR)
Influence of Disease-Modifying Therapy on the Efficacy of Vutrisiran in Transthyretin Cardiac Amyloidosis
Journal of the American College of Cardiology
Transthyretin Amyloidosis (ATTR)
Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis with Cardiomyopathy: Insights From HELIOS-B
Journal of the American College of Cardiology
Connect with Alnylam Medical
For further information or questions related to Alnylam's clinical data, connect with Alnylam Medical.
Medical Information
For Medical Information inquiries, please submit your question using the email below.
For country-specific Medical Information contact details, please navigate to the individual country sites located at Alnylam.com.
Adverse Events/Product Complaints
To report an adverse event or to submit a product complaint, please use the email below.
For country-specific contact details, please navigate to the individual country sites located at Alnylam.com.
Clinical Trials
For clinical trial inquiries, please use the contact options below.
